2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)

BACKGROUND: DLX is an IV/oral fluoroquinolone with no QT restrictions, and activity against Gram-positive, Gram-negative and atypical pathogens. DLX is approved for treatment of ABSSSI including those due to MRSA and Gram-negative pathogens. A Phase 3 trial of patients with CABP was recently complet...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Open Forum Infect Dis
Autors principals: Salata, Robert, Alvarez-Sala, Rodolfo, Horcajada, Juan P, Lawrence, Laura, Quintas, Megan, Li, Yang, Cammarata, Sue
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2019
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6810364/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofz360.1910
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars